• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular Therapeutix settles Mati Therapeutics patent spat, logs CMS win for Dextenza

May 1, 2019 By Fink Densford

Ocular Therapeutix logo

Ocular Therapeutix (NSDQ:OCUL) said this week it settled a patent spat with Mati Therapeutics and that it won reimbursement from the Centers for Medicare and Medicaid Services for its Dextenza ocular insert.

In an SEC filing posted yesterday, the Bedford, Mass.-based company said that it settled its litigation with Mati Therapeutics and that both parties dismissed all claims and counterclaims pending against each other in the U.S. District Court for the District of Delaware.

Through the settlement agreement, both parties granted each other a limited covenant not to sue regarding infringement by Ocular Therapeutix’s Dextenza product, as approved under its New Drug Application number 208742. No financial considerations were paid by either party, and all other terms of the deal were not disclosed, according to an SEC filing.

In a release posted today, Ocular Therapeutix said that CMS has included its Dextenza product, an ocular insert designed to release dexamethasone to relieve pain following ophthalmic surgery, on its list of products preliminarily recommended for a new dedicated Healthcare Common Procedure Coding System J-Code, effective January 1, 2020.

The Dextenza device is designed to deliver drugs for up to 30 days following treatment in a physician’s office. Ocular Therapeutix is positioning its product as a way to eliminate the current standard of care for post-surgical pain – topical steroid eye drops.

The company said it believes that receipt of a J-code will “facilitate reimbursement for a greater number of patients to be treated with Dextenza,” according to a press release.

Ocular Therapeutix said that it also submitted an application for an HCPCS C-code for transitional pass-through payment status and that it expects notification from CMS by the middle of this year.

“We are pleased that CMS has recommended a unique J-code for Dextenza. Finalization of this recommendation later this year would be an important achievement for the Company and for the potential commercial success of Dextenza,” prez & CEO Antony Mattessich said in a press release.

Last month, Ocular Therapeutix said that the FDA has accepted a new supplemental New Drug Application for its Dextenza.

Filed Under: Business/Financial News, Featured, Legal News, Optical/Ophthalmic Tagged With: Ocular Therapeutix

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS